Aquestive Therapeutics, Inc. (AQST)
AQST Stock Price Chart
Explore Aquestive Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze AQST price movements and trends.
AQST Company Profile
Discover essential business fundamentals and corporate details for Aquestive Therapeutics, Inc. (AQST) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
25 Jul 2018
Employees
142.00
Website
https://www.aquestive.comCEO
Daniel Barber
Description
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
AQST Financial Timeline
Browse a chronological timeline of Aquestive Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.10, while revenue estimate is $11.42m.
Earnings released on 13 May 2026
EPS came in at -$0.07 surpassing the estimated -$0.14 by +50.00%, while revenue for the quarter reached $14.45m , beating expectations by +32.58%.
Earnings released on 4 Mar 2026
EPS came in at -$0.26 falling short of the estimated -$0.13 by -100.00%, while revenue for the quarter reached $13.02m , missing expectations by -2.04%.
Earnings released on 5 Nov 2025
EPS came in at -$0.14 falling short of the estimated -$0.11 by -27.27%, while revenue for the quarter reached $12.81m , missing expectations by -1.05%.
Earnings released on 11 Aug 2025
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%, while revenue for the quarter reached $10.00m , missing expectations by -17.98%.
Earnings released on 12 May 2025
EPS came in at -$0.24 falling short of the estimated -$0.17 by -41.18%, while revenue for the quarter reached $8.72m , missing expectations by -28.70%.
Earnings released on 5 Mar 2025
EPS came in at -$0.19 falling short of the estimated -$0.14 by -35.71%, while revenue for the quarter reached $11.87m , missing expectations by -9.50%.
Earnings released on 4 Nov 2024
EPS came in at -$0.13 falling short of the estimated -$0.12 by -8.33%, while revenue for the quarter reached $13.54m , beating expectations by +3.17%.
Earnings released on 6 Aug 2024
EPS came in at -$0.03 surpassing the estimated -$0.11 by +72.73%, while revenue for the quarter reached $20.10m , beating expectations by +62.35%.
Earnings released on 7 May 2024
EPS came in at -$0.17 falling short of the estimated -$0.09 by -88.89%, while revenue for the quarter reached $12.05m , missing expectations by -1.69%.
Earnings released on 5 Mar 2024
EPS came in at -$0.12 falling short of the estimated -$0.08 by -50.00%, while revenue for the quarter reached $13.21m , beating expectations by +13.55%.
Earnings released on 6 Nov 2023
EPS came in at -$0.03 surpassing the estimated -$0.11 by +72.73%, while revenue for the quarter reached $13.00m , beating expectations by +11.80%.
Earnings released on 7 Aug 2023
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%, while revenue for the quarter reached $13.24m , beating expectations by +20.26%.
Earnings released on 2 May 2023
EPS came in at $0.11 surpassing the estimated -$0.10 by +210.00%, while revenue for the quarter reached $11.13m , beating expectations by +12.24%.
Earnings released on 7 Mar 2023
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%, while revenue for the quarter reached $10.68m , beating expectations by +2.51%.
Earnings released on 1 Nov 2022
EPS came in at -$0.23 surpassing the estimated -$0.30 by +23.33%, while revenue for the quarter reached $11.46m , beating expectations by +4.19%.
Earnings released on 2 Aug 2022
EPS came in at -$0.36 surpassing the estimated -$0.41 by +12.20%, while revenue for the quarter reached $13.27m , beating expectations by +25.47%.
Earnings released on 3 May 2022
EPS came in at -$0.32 surpassing the estimated -$0.45 by +28.89%, while revenue for the quarter reached $12.27m , beating expectations by +21.13%.
Earnings released on 8 Mar 2022
EPS came in at -$0.38 falling short of the estimated -$0.37 by -2.70%, while revenue for the quarter reached $11.08m , beating expectations by +18.33%.
Earnings released on 2 Nov 2021
EPS came in at -$0.37 surpassing the estimated -$0.40 by +7.50%, while revenue for the quarter reached $13.29m , beating expectations by +20.68%.
Earnings released on 3 Aug 2021
EPS came in at -$0.33 surpassing the estimated -$0.42 by +21.43%, while revenue for the quarter reached $15.35m , meeting expectations.
AQST Stock Performance
Access detailed AQST performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
